Loading stock data…
Enovis Corporation (ENOV)
$22.02-0.69 (-3.04%)
Market ClosedLast close Jun 29
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enovis Corporation in the Healthcare sector is trading at $22.02 with a market capitalization of $1.2B. Wall Street consensus targets $42.30 (10 analysts), implying a +92.1% move over the next 12 months. The stock is currently near its 52-week low of $20.55, remaining 15.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +92.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $589.15M↑ | $575.76M↑ | $548.91M↓ | $564.54M↑ | $558.83M |
| Gross Profit | $365.49M↑ | $349.42M↑ | $328.91M↓ | $334.70M↑ | $332.23M |
| Operating Income | $9.24M↓ | $48.25M↑ | -$8.14M↑ | -$16.08M↑ | -$42.91M |
| Net Income | -$8.76M↑ | -$520.59M↑ | -$571.15M↓ | -$36.74M↑ | -$55.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.00%
Volume
Today's trading volume
1.07M
Recent News
1 Oversold Stock Primed to Rebound and 2 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
Spotting Winners: Enovis (NYSE:ENOV) And Medical Devices & Supplies - Specialty Stocks In Q1
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Enovis (NYSE:ENOV) and its peers.
Assessing Enovis (ENOV) Valuation After Recent Share Price Weakness
Enovis stock performance snapshot Enovis (ENOV) has been under pressure recently, with the stock down 8.3% on the day and lower over the past month, past 3 months and year, while longer term returns also show declines. At a last close of US$21.97, Enovis carries a market value of about US$1.38b. The company reports annual revenue of US$2,278.37m and a net loss of US$1,135.42m, giving investors a loss-making medical technology business to assess. See our latest analysis for Enovis. The recent...
Brookdale Senior May 2026 Occupancy Volume Rises to 82.5%
BKD's occupancy climbs to 82.5% in May, extending a four-quarter growth streak and supporting its 2026 revenue and EBITDA outlook.
Veeva's Falcon and Vault AI: When Could AI Become a Revenue Driver?
VEEV's Falcon and Vault AI deepen workflow automation across life sciences, while management expects AI revenues to remain immaterial in fiscal 2027.